Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Other Accumulated Expenses (2022 - 2026)

Standard Biotools has reported Other Accumulated Expenses over the past 4 years, most recently at $3.6 million for Q4 2025.

  • Quarterly Other Accumulated Expenses fell 23.06% to $3.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.6 million through Dec 2025, down 23.06% year-over-year, with the annual reading at $3.6 million for FY2025, 23.06% down from the prior year.
  • Other Accumulated Expenses was $3.6 million for Q4 2025 at Standard Biotools, up from $2.5 million in the prior quarter.
  • Over five years, Other Accumulated Expenses peaked at $7.3 million in Q3 2024 and troughed at $714000.0 in Q3 2023.
  • The 4-year median for Other Accumulated Expenses is $4.0 million (2023), against an average of $3.9 million.
  • Year-over-year, Other Accumulated Expenses soared 917.51% in 2024 and then plummeted 83.63% in 2025.
  • A 4-year view of Other Accumulated Expenses shows it stood at $913000.0 in 2022, then surged by 341.73% to $4.0 million in 2023, then grew by 15.5% to $4.7 million in 2024, then dropped by 23.06% to $3.6 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Other Accumulated Expenses are $3.6 million (Q4 2025), $2.5 million (Q3 2025), and $1.1 million (Q2 2025).